Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19

FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate